-

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world.

Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes.

"Exact Sciences’ success starts with our people, and winning the Gallup Exceptional Workplace Award for the second consecutive year is a testament to the dedication of our incredible team," said Sarah Condella, executive vice president of human resources at Exact Sciences. "Our culture is built on shared values, collaboration, and a relentless commitment to our mission. By fostering an environment where employees feel engaged, supported, and empowered, we continue to make a meaningful impact on patients and advance our fight against cancer."

The GEWA winners’ ratio of engaged employees to actively disengaged employees is 11 times higher than the global average. Worldwide, only 23% of employees are engaged — that is, committed to their work and connected to their workplace — and just 33% of employees in the U.S. workforce are engaged. Seventy percent of employees at winning GEWA organizations are engaged.

“Congratulations to this year’s Gallup Exceptional Workplace Award winners for setting the standard for a thriving workplace. Your commitment to creating an environment where employees feel valued, heard and empowered to do their best work is truly remarkable. By prioritizing both people and performance, you are shaping the future of work and proving that exceptional workplaces drive real results,” said Jon Clifton, Gallup’s chief executive officer.

Gallup’s meta-analysis on team engagement and performance is the most comprehensive workplace study ever conducted, with data on more than 3.3 million employees in 347 organizations across 53 industries and 90 countries. The company’s research shows that highly engaged organizations significantly outperform their peers in important business outcomes, including customer ratings, profitability, productivity, turnover, safety incidents, shrinkage, absenteeism, quality, well-being, and organizational citizenship.

For a complete list of GEWA winners and more about the selection process, visit the winners page.

Exact Sciences is looking for talented people who are passionate about helping patients and fighting cancer. For more information and to view a complete list of job openings, visit the company’s careers site.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

About Gallup

Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students, and citizens than any other organization in the world.

Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

Gallup
media@gallup.com

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

Gallup
media@gallup.com

More News From Exact Sciences Corp.

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with s...

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of clinical evidence, the test has become a global standard-of-care by identifying patients who are – and are not – likely t...

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early...
Back to Newsroom